LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Stock List・ResMed Inc

ResMed Inc

Closed

SectorHealthcare

206.69 -1.51

Buy Sell

Overview

Share price change

24h

Current

Min

206.24

Max

210.48

Key metrics
By Trading Economics
Income	6.1M 399M
Sales	8.6M 1.4B
P/E Sector Avg	19.758 49.8
EPS	2.86
Dividend yield	1.14
Profit margin	27.856
Employees	10,600
EBITDA	-67M 500M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+27.87% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	1.14% 2.25%
Next Earnings	30 Jul 2026
Next Dividend date	18 Jun 2026
Next Ex Dividend date	14 May 2026

Market Stats
By TradingEconomics
Market Cap	-2B 30B
Previous open	208.2
Previous close	206.69

News Sentiment

By Acuity

50%

166 / 347 Healthcare

ResMed Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 May 2026, 23:58 UTC

Earnings

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 May 2026, 22:57 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 May 2026, 23:52 UTC

Earnings

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 May 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 May 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 May 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 May 2026, 23:11 UTC

Earnings

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 May 2026, 23:06 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 May 2026, 23:05 UTC

Earnings

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 May 2026, 23:04 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 May 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 May 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 May 2026, 23:02 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 May 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 May 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 May 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 May 2026, 22:42 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 May 2026, 22:33 UTC

Earnings

Acquisitions, Mergers, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 May 2026, 22:32 UTC

Earnings

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 May 2026, 22:31 UTC

Earnings

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 May 2026, 22:31 UTC

Earnings

Macquarie: 68% of FY Income From International >MQG.AU

7 May 2026, 22:30 UTC

Earnings

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 May 2026, 22:30 UTC

Earnings

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 May 2026, 22:29 UTC

Earnings

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 May 2026, 22:28 UTC

Earnings

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 May 2026, 22:28 UTC

Earnings

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 May 2026, 22:27 UTC

Earnings

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 May 2026, 22:27 UTC

Earnings

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 May 2026, 22:26 UTC

Earnings

Macquarie to End Share Buyback Extended in November>MQG.AU

7 May 2026, 22:25 UTC

Earnings

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer Comparison

Price change

ResMed Inc Forecast

Price Target

By TipRanks

27.87% upside

12 Months Forecast

Average 264.56 USD 27.87%

High 340 USD

Low 225 USD

Based on 13 Wall Street analysts offering 12 month price targets forResMed Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to ResMed Inc - Dist in the past 3 months.

Sentiment

By Acuity

166 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.